BK Virus Infection Pipeline Analysis: Key Pharma Players Set to Develop Innovative Therapies and Explore Innumerable Opportunities

Posted on
by

BK Virus Infection Pipeline Analysis

The BK Virus Infection Pipeline Insights report from DelveInsight gives a detailed overview of the pipeline therapeutics in various clinical and preclinical phases of development, as well as their introduction and how the market is projected to change as a result across the BK Virus Infection domain.

The BK Virus Infection Pipeline Analysis study provides a 360-degree picture of the therapeutics landscape for BK Virus Infection emerging therapies by development stage, product type, method of administration, molecule type, and MOA.

The BK Virus Infection pipeline report lays down the business opportunities, threats, prospective collaborations, strong competitors, and growth strategies. 

Some of the key highlights from the BK Virus Infection Pipeline report:

  • ALVR 105, commonly known as Viralym-M, is a human leukocyte antigen (HLA) matched multivirus-specific T cell candidate being developed by AlloVir. Viralym-M is intended to bridge the gap between conditioning and immune system reconstitution by providing bridging immunity.
  • Out of all the emerging therapies, Viralym-M (ALVR 105) is in phase III of clinical development.
  • The BK Virus Infection report provides the assessment of therapies by Stage and route of administration. Number of therapies for various ROAs present in different phases have been provided in graphical as well as tabulated form.
  • Key pharma players developing  BK Virus Infection pipeline therapies include AlloVir, Amplyx Pharmaceuticals, SL VAXiGEN, Hybridize Therapeutics, and Memo Therapeutics.

Request for Sample @ BK Virus Infection Pipeline Insights and Outlook

The BK virus is one of 13 polyomaviruses that have been identified. Antibodies to BKV can be discovered in 80 to 90 percent of persons around the world, indicating that they have been infected or exposed to the virus. 

BKV infection is frequently asymptomatic or accompanied with mild flu-like symptoms when it first occurs. BKV stays dormant, or latent, in the kidney and bladder after primary infection. BKV can reactivate and cause serious sickness if your immune system is impaired. BKV can cause the transplanted kidney to fail in patients who have had a kidney transplant.

BK Virus Infection Pipeline Analysis: Drug Profile 

Viralym-M (ALVR 105): AlloVir 

ALVR 105, commonly known as Viralym-M, is a human leucocyte antigen (HLA) matched multivirus-specific T cell candidate being developed by AlloVir. Viralym-M is intended to bridge the gap between conditioning and immune system reconstitution by providing bridging immunity.

Viralym-M may significantly reduce or avoid virus-associated morbidity and mortality and considerably improve patient outcomes by restoring immunity during this period of severe immunological weakness.

Dive deeper to know more @ BK Virus Infection therapeutics and drugs pipeline

Key Pipeline Therapies along with Companies 

  • Viralym-M (ALVR105): AlloVir
  • MAU868: Amplyx Pharmaceuticals 
  • SL-V10: SL VAXiGEN
  • HYB-BKV: Hybridize Therapeutics
  • MTX-005: Memo Therapeutics

BK Virus Infection Pipeline Therapeutics Assessment

  • By Product Type
    • Monotherapy
  • By Stage
    • Discovery 
    • Pre-clinical
    • Phase I
    • Phase II
    • Phase III
    • Pre-registration 
  • By Route of Administration
    • Intravenous
  • By Molecule Type
    • T lymphocyte cell therapies 
  • By Mechanism of Action
    • Immunologic cytotoxicity
    • T lymphocyte replacements

Got queries? Reach out for more information @ BK Virus Infection Drug Pipeline Assessment

Scope of the Report

  • Coverage: Global
  • Key Market Players:AlloVir, Amplyx Pharmaceuticals, SL VAXiGEN, Hybridize Therapeutics, Memo Therapeutics, among others.
  • Key Pipeline Therapies:Viralym-M (ALVR105), MAU868, SL-V10, HYB-BKV, MTX-005, among others.

Table of Content 

1

Report Introduction

2

BK Virus Infection

3

BK Virus Infection Current Treatment Patterns

4

BK Virus Infection – DelveInsight’s Analytical Perspective

5

Therapeutic Assessment

6

BK Virus Infection Late Stage Products (Phase-III)

7

BK Virus Infection Mid Stage Products (Phase-II)

8

Early Stage BK Virus Infection Products (Phase-I)

9

BK Virus Infection Pre-clinical Products and Discovery Stage Products

10

Inactive Products

11

Dormant Products

12

BK Virus Infection Discontinued Products

13

BK Virus Infection Product Profiles

14

BK Virus Infection Key Companies

15

BK Virus Infection Key Products

16

Dormant and Discontinued Products

17

BK Virus Infection Unmet Needs

18

BK Virus Infection Future Perspectives

19

BK Virus Infection Analyst Review

20

Appendix

21

Report Methodology

Related Reports:

BK virus (BKV) Infection Market

BK virus (BKV) Infection Epidemiology

COVID 19 (Novel Coronavirus 19) Competitive Landscape

Congenital Myasthenic Syndromes Market

Colonoscopes Pipeline

Panic Disorder Market

Acute Kidney Injury (AKI) Market

Acute Renal Failure (ARF) Market

Infliximab Biosimilars Pipeline

Chronic kidney disease (CKD) Market

Persistent Epithelial Defect (PED) Market

Orthopedic Bone Cement Market

Noonan Syndrome Market

Zollinger-Ellison Syndrome Market

Merkel Cell Carcinoma Market

Catheter-Related Bloodstream Infections Market

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences providing comprehensive end-to-end solutions to improve performance.  

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/